ALGS
NASDAQ · Biotechnology
Aligos Therapeutics Inc
$7.32
+0.83 (+12.79%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.95M | 10.09M | 11.15M |
| Net Income | -2,050,765 | -1,613,644 | -1,815,730 |
| EPS | — | — | — |
| Profit Margin | -20.6% | -16.0% | -16.3% |
| Rev Growth | +6.7% | -9.4% | -9.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 3.73M | 3.40M | 3.50M |
| Total Equity | 25.54M | 25.89M | 24.88M |
| D/E Ratio | 0.15 | 0.13 | 0.14 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -1,999,521 | -2,029,249 | -2,356,621 |
| Free Cash Flow | -1,287,997 | -1,586,727 | -1,930,971 |